Join
Live feed
·
PRReleasevia Quantisnow
Acumen Pharmaceuticals Inc. logo

Acumen Pharmaceuticals to Present Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer's Disease During Featured Research Session at the Alzheimer's Association International Conference (AAIC®) 2023

ByQuantisnow·Wall Street's wire, on your screen.
ABOS· Acumen Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABOS (Acumen Pharmaceuticals Inc.) and more on Quantisnow.